 - Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome SBS in Q2; total stool output TSO is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP glucose-dependent insulinotropic polypeptide monoclonal antibody from Lobesity - - Current capital is sufficient to fund operations into 2023 - RALEIGH, NC ACCESSWIRE August 12, 2021 9 Meters Biopharma, Inc. Nasdaq:NMTR the Company is a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases or unique GI biology, today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021. Key Business Highlights In July, announced acquisition of humanized anti-GIP monoclonal antibody from Lobesity for the treatment of Prader-Willi Syndrome In June, announced the initiation of Phase 2 VIBRANT trial of vurolenatide for SBS In May, received USAN approval to use the designated nonproprietary name vurolenatide for its long-acting GLP-1 agonist for SBS In May, announced publication in Journal of Clinical Investigation describing successful use of larazotide for treating multisystem inflammatory syndrome in children MIS-C resulting from COVID-19 infection In April, announced that the Duke Clinical Research Institute will support Phase 2 VIBRANT trial in SBS In April, announced a collaboration with Celiac Disease Foundation to support clinical trial enrollment in Phase 3 study, CeDLara, for larazotide in celiac disease In April, closed a follow on offering with net proceeds of approximately 31.5 million to the Company Cash as of June 30, 2021 of 64M is expected to provide sufficient cash runway into 2023 based on the current operating plan, inclusive of the recently announced Lobesity transaction John Temperato, President CEO of 9 Meters Biopharma, commented: We continue to execute on our business plan and we anticipate to be able to release Phase 2 data with vurolenatide for SBS in Q4 of 2021. 